期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Limited joint mobility syndrome in diabetes mellitus: A minireview 被引量:2
1
作者 Esther G Gerrits Gijs W Landman +1 位作者 Leonie Nijenhuis-Rosien Henk J Bilo 《World Journal of Diabetes》 SCIE CAS 2015年第9期1108-1112,共5页
Limited joint mobility syndrome(LJMS) or diabetic cheiroarthropathy is a long term complication of diabetes mellitus. The diagnosis of LJMS is based on clinical features: progression of painless stiffness of hands and... Limited joint mobility syndrome(LJMS) or diabetic cheiroarthropathy is a long term complication of diabetes mellitus. The diagnosis of LJMS is based on clinical features: progression of painless stiffness of hands and fingers, fixed flexion contractures of the small hand and foot joints, impairment of fine motion and impaired grip strength in the hands. As the syndrome progresses, it can also affect other joints. It is important to properly diagnose such a complication as LJMS. Moreover, it is important to diagnose LJMS because it is known that the presence of LJMS is associated with micro- and macrovascular complications of diabetes. Due to the lack of curative treatment options, the suggested method to prevent or decelerate the development of LJMS is improving or maintaining good glycemic control. Daily stretching excercises of joints aim to prevent or delay progression of joint stiffness, may reduce the risk of inadvertent falls and will add to maintain quality of life. 展开更多
关键词 DIABETIC cheiroarthropathy Limited jointmobility DIABETES MELLITUS Joint STIFFNESS advancedglycation endproducts
暂未订购
Advanced-glycation end-products axis:A contributor to the risk of severe illness from COVID-19 in diabetes patients
2
作者 Armando Rojas Cristian Lindner +1 位作者 Ileana Gonzàlez Miguel Angel Morales 《World Journal of Diabetes》 SCIE 2021年第5期590-602,共13页
Compelling pieces of evidence derived from both clinical and experimental research has demonstrated the crucial role of the receptor for advanced-glycation end-products(RAGE)in orchestrating a plethora of proinflammat... Compelling pieces of evidence derived from both clinical and experimental research has demonstrated the crucial role of the receptor for advanced-glycation end-products(RAGE)in orchestrating a plethora of proinflammatory cellular responses leading to many of the complications and end-organ damages reported in patients with diabetes mellitus(DM).During the coronavirus disease 2019(COVID-19)pandemic,many clinical reports have pointed out that DM increases the risk of COVID-19 complications,hospitalization requirements,as well as the overall severe acute respiratory syndrome coronavirus 2 case-fatality rate.In the present review,we intend to focus on how the basal activation state of the RAGE axis in common preexisting conditions in DM patients such as endothelial dysfunction and hyperglycemia-related prothrombotic phenotype,as well as the contribution of RAGE signaling in lung inflammation,may then lead to the increased mortality risk of COVID-19 in these patients.Additionally,the crosstalk between the RAGE axis with either another severe acute respiratory syndrome coronavirus 2 receptor molecule different of angiotensin-converting enzyme 2 or the renin-angiotensin system imbalance produced by viral infection,as well as the role of this multi-ligand receptor on the obesity-associated lowgrade inflammation in the higher risk for severe illness reported in diabetes patients with COVID-19,are also discussed. 展开更多
关键词 COVID-19 Diabetes mellitus Advanced glycation ALARMINS advancedglycation end-products axis Inflammation
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部